Pfizer’s Ibrance Successor Moves Forward with New Study Data

Pfizer’s Ibrance successor moves forward with new study data

The drug, which one analyst described as a “critical” part of Pfizer’s oncology strategy, represents a possible improvement upon Ibrance and other, similar breast cancer medicines from Eli Lilly and Novartis.

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial - Regional Media News

March 17 (Reuters) - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by 40% in patients with breast cancer. Here are some details: * Pfizer's atirmociclib in combination with fulvestrant, ahormone therapy, was being tested in a mid-stage study inpatients whose cancer had spread and had received priortreatment. * The experimental drug combo was being compared tofulvestrant or everolimus plus ex…

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients initiated atirmociclib within 3 months of prior CDK4/6 inhibitor therapy Results strengthen confidence in atirmociclib as a potential first-in-class, next-generation cell cycle inhibitor backbone [...] The post Pfizer Announces Positive Topline Phase 2 Re…

Pfizer's next-gen breast cancer data; Bristol Myers' PRMT5 candidate

Plus, news about Genentech, Mestag and BioVie: 📊 Pfizer says next-gen breast cancer drug succeeds in Phase 2: The company is developing a CDK4 inhibitor called atirmociclib as a successor to its breast cancer drug ...